Deployment aims to improve serialization efficiency by 45% and enhance regulatory compliance across global export markets
Growth driven by strong performance across Sugar Free, RiteBite Max Protein, Everyuth, Glucon-D and Nutralite portfolios
The company reported free cash flow of Rs. 2,590 Mn for FY26
AstraZeneca highlighted the move as a major step toward earlier intervention in curable disease
This positions its platform as a rapidly evolving engine for next-generation genetic medicine
Tecentriq SC reduces treatment administration time by nearly 80 percent and has the potential to lower indirect treatment costs
Baxfendy works in a fundamentally different way from current therapies
Next-generation berberine formulation developed with BioSOLVE Technology targets metabolic health, blood sugar balance, and weight management
Access to genomic testing, not therapy cost, is the biggest challenge
Antiviral injection addressing CMV and HSV infections had US market sales of nearly $15 million in the last 12 months
Subscribe To Our Newsletter & Stay Updated
